Daniel Cruceriu1,2, Oana Baldasici1, Ovidiu Balacescu3,4, Ioana Berindan-Neagoe5,6,7. 1. Department of Functional Genomics and Experimental Pathology, The Oncology Institute "Prof. Dr. Ion Chiricuta", Cluj-Napoca, Romania. 2. Department of Molecular Biology and Biotechnology, "Babes-Bolyai" University, Cluj-Napoca, Romania. 3. Department of Functional Genomics and Experimental Pathology, The Oncology Institute "Prof. Dr. Ion Chiricuta", Cluj-Napoca, Romania. ovidiubalacescu@iocn.ro. 4. 11th Department of Medical Oncology, "Iuliu Hatieganu" University of Medicine and Pharmacy, 34-36 Republicii Street, 400015, Cluj-Napoca, Romania. ovidiubalacescu@iocn.ro. 5. Department of Functional Genomics and Experimental Pathology, The Oncology Institute "Prof. Dr. Ion Chiricuta", Cluj-Napoca, Romania. ioana.neagoe@umfcluj.ro. 6. Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania. ioana.neagoe@umfcluj.ro. 7. MedFuture Research Center for Advanced Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 23 Marinescu Street, 400337, Cluj-Napoca, Romania. ioana.neagoe@umfcluj.ro.
Abstract
BACKGROUND: Breast cancer is the most prevalent cancer among women worldwide and the fifth cause of death among all cancer patients. Breast cancer development is driven by genetic and epigenetic alterations, with the tumor microenvironment (TME) playing an essential role in disease progression and evolution through mechanisms like inflammation promotion. TNF-α is one of the essential pro-inflammatory cytokines found in the TME of breast cancer patients, being secreted both by stromal cells, mainly by tumor-associated macrophages, and by the cancer cells themselves. In this review, we explore the biological and clinical impact of TNF-α in all stages of breast cancer development. First of all, we explore the correlation between TNF-α expression levels at the tumor site or in plasma/serum of breast cancer patients and their respective clinical status and outcome. Secondly, we emphasize the role of TNF-α signaling in both estrogen-positive and -negative breast cancer cells. Thirdly, we underline TNF-α involvement in epithelial-to-mesenchymal transition (EMT) and metastasis of breast cancer cells, and we point out the contribution of TNF-α to the development of acquired drug resistance. CONCLUSIONS: Collectively, these data reveal a pro-tumorigenic role of TNF-α during breast cancer progression and metastasis. We systemize the knowledge regarding TNF-α-related therapies in breast cancer, and we explain how TNF-α may act as both a target and a drug in different breast cancer therapeutic approaches. By corroborating the known molecular effects of TNF-α signaling in breast cancer cells with the results from several preclinical and clinical trials, including TNF-α-related clinical observations, we conclude that the potential of TNF-α in breast cancer therapy promises to be of great interest.
BACKGROUND:Breast cancer is the most prevalent cancer among women worldwide and the fifth cause of death among all cancerpatients. Breast cancer development is driven by genetic and epigenetic alterations, with the tumor microenvironment (TME) playing an essential role in disease progression and evolution through mechanisms like inflammation promotion. TNF-α is one of the essential pro-inflammatory cytokines found in the TME of breast cancerpatients, being secreted both by stromal cells, mainly by tumor-associated macrophages, and by the cancer cells themselves. In this review, we explore the biological and clinical impact of TNF-α in all stages of breast cancer development. First of all, we explore the correlation between TNF-α expression levels at the tumor site or in plasma/serum of breast cancerpatients and their respective clinical status and outcome. Secondly, we emphasize the role of TNF-α signaling in both estrogen-positive and -negative breast cancer cells. Thirdly, we underline TNF-α involvement in epithelial-to-mesenchymal transition (EMT) and metastasis of breast cancer cells, and we point out the contribution of TNF-α to the development of acquired drug resistance. CONCLUSIONS: Collectively, these data reveal a pro-tumorigenic role of TNF-α during breast cancer progression and metastasis. We systemize the knowledge regarding TNF-α-related therapies in breast cancer, and we explain how TNF-α may act as both a target and a drug in different breast cancer therapeutic approaches. By corroborating the known molecular effects of TNF-α signaling in breast cancer cells with the results from several preclinical and clinical trials, including TNF-α-related clinical observations, we conclude that the potential of TNF-α in breast cancer therapy promises to be of great interest.
Authors: K Kimura; T Taguchi; I Urushizaki; R Ohno; O Abe; H Furue; T Hattori; H Ichihashi; K Inoguchi; H Majima Journal: Cancer Chemother Pharmacol Date: 1987 Impact factor: 3.333
Authors: O J Jupp; S M McFarlane; H M Anderson; A F Littlejohn; A A Mohamed; R H MacKay; P Vandenabeele; D J MacEwan Journal: Biochem J Date: 2001-11-01 Impact factor: 3.857
Authors: Srinivasan Madhusudan; Martin Foster; Sethupathi R Muthuramalingam; Jeremy P Braybrooke; Susan Wilner; Kulwinder Kaur; Cheng Han; Susan Hoare; Frances Balkwill; Denis C Talbot; Trivadi S Ganesan; Adrian L Harris Journal: Clin Cancer Res Date: 2004-10-01 Impact factor: 12.531
Authors: Leya Groysman; Lindsey Carlsen; Kelsey E Huntington; Wen H Shen; Lanlan Zhou; Wafik S El-Deiry Journal: Am J Cancer Res Date: 2021-12-15 Impact factor: 6.166
Authors: Sherihan Salaheldin Abdelhamid Ibrahim; Sarah A Abd El-Aal; Ahmed M Reda; Samar El Achy; Yasmine Shahine Journal: Sci Rep Date: 2022-07-07 Impact factor: 4.996
Authors: Ahmed A H Abdellatif; Mansour Alsharidah; Osamah Al Rugaie; Hesham M Tawfeek; Nahla Sameh Tolba Journal: Drug Des Devel Ther Date: 2021-05-13 Impact factor: 4.162